Andreessen Horowitz led a $19m Series A funding round in BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform. The round had participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors. "Our mission is to improve human health by making it far easier to create advanced, next-generation antibody and protein therapeutics. BigHat is transforming antibody design from bulk screening to data-driven engineering to give precise control over the antibodies’ molecular properties. Leveraging recent advances in synthetic biology and machine learning, our platform measures and optimizes antibodies for the biophysical and functional properties needed for cutting-edge therapeutic applications,” Mark DePristo, BigHat Co-founder and CEO.